These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34547923)

  • 1. Factors Associated with Re-Resection in T1 Bladder Cancer: Identifying Patients Who Do Not Receive Guideline-Concordant Care at the Population Level.
    Wettstein MS; Baxter NN; Sutradhar R; Mamdani M; Song P; Qadri SR; Bhalla G; Li K; Liu N; van der Kwast T; Hermanns T; Kulkarni GS
    J Urol; 2022 Feb; 207(2):314-323. PubMed ID: 34547923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons.
    Wettstein MS; Baxter NN; Sutradhar R; Mamdani M; Song P; Qadri SR; Li K; Liu N; van der Kwast T; Hermanns T; Kulkarni GS
    Urol Oncol; 2022 Apr; 40(4):165.e1-165.e8. PubMed ID: 35135701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.
    Klän R; Loy V; Huland H
    J Urol; 1991 Aug; 146(2):316-8. PubMed ID: 1856924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study.
    Wettstein MS; Baxter NN; Sutradhar R; Mamdani M; Song P; Qadri SR; Li K; Liu N; van der Kwast T; Hermanns T; Kulkarni GS
    BJU Int; 2022 Feb; 129(2):258-268. PubMed ID: 34674366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
    PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors].
    Gaya JM; Palou J; Cosentino M; Patiño D; Rodríguez-Faba O; Villavicencio H
    Actas Urol Esp; 2012 Oct; 36(9):539-44. PubMed ID: 22710093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines.
    Sakano S; Matsuyama H; Takai K; Yoshihiro S; Kamiryo Y; Shirataki S; Kaneda Y; Hashimoto O; Joko K; Suga A; Yamamoto M; Hayashida S; Baba Y; Aoki A;
    BJU Int; 2011 May; 107(10):1598-604. PubMed ID: 21087393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Ferro M; Vartolomei MD; Cantiello F; Lucarelli G; Di Stasi SM; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdonà S; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Verze P; Battaglia M; Serretta V; Russo GI; Morgia G; Musi G; de Cobelli O; Mirone V; Shariat SF
    Urol Int; 2018; 101(1):7-15. PubMed ID: 29975950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
    J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients.
    Picozzi S; Ricci C; Gaeta M; Ratti D; Macchi A; Casellato S; Bozzini G; Carmignani L
    J Urol; 2012 Dec; 188(6):2046-54. PubMed ID: 23083867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
    Das A; Cohen JE; Ko OS; Jordan BJ; Glaser AP; Auffenberg GB; Meeks JJ
    J Urol; 2021 Mar; 205(3):693-700. PubMed ID: 33021430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter?
    Ucpinar B; Erbin A; Ayranci A; Caglar U; Alis D; Basal S; Sarilar O; Akbulut MF
    J BUON; 2019; 24(4):1659-1665. PubMed ID: 31646822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?
    Kaimakliotis HZ; Monn MF; Cary KC; Pedrosa JA; Rice K; Masterson TA; Gardner TA; Hahn NM; Foster RS; Bihrle R; Cheng L; Koch MO
    Urol Oncol; 2014 Aug; 32(6):833-8. PubMed ID: 24954925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review.
    Mori K; Miura N; Babjuk M; Karakiewicz PI; Mostafaei H; Laukhtina E; Quhal F; Motlagh RS; Pradere B; Kimura S; Egawa S; Shariat SF
    Urol Oncol; 2020 Oct; 38(10):774-782. PubMed ID: 32654948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor.
    Hassan O; Murati Amador B; Lombardo KA; Salles D; Cuello F; Marwaha AS; Daniels MJ; Kates M; Bivalacqua TJ; Matoso A
    World J Urol; 2020 Feb; 38(2):389-395. PubMed ID: 31030230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.